Shanghai Hile Bio-Tech reports strong 2024, new dividend plan

Shanghai Hile Bio-Technology (SSE:603718) reports a significant turnaround in its 2024 financial year, driven by strategic restructuring. The company posted a 12.59% increase in revenue, reaching CNY 271.04 million, and a substantial 172.28% rise in net profit attributable to shareholders, clocking in at CNY 171.18 million. This surge is attributed to the successful divestiture of loss-making animal biologics and the focused acquisition of human biologics assets, specifically in oral regeneration.